SEARCH

SEARCH BY CITATION

References

  • 1
    Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000; 61: 3626.
  • 2
    Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 61926.
  • 3
    O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14: 10411.
  • 4
    Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 1507.
  • 5
    Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 18427.
  • 6
    Papatheodoridis GV, Sevastianos V, Burroughs AK. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transpl 2003; 3: 2508.
  • 7
    Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 20710.
  • 8
    Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33: 30812.
  • 9
    Manolakopoulos S, Karatapanis S, Elefsiniotis J, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004; 99: 5763.
    Direct Link:
  • 10
    Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B. Lancet Infect Dis 2008; 8: 16778.
  • 11
    Papatheodoridis GV, Dimou E, Laras A, et al. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 21926.
  • 12
    Merle P, Trepo C. Therapeutic management of hepatitis B-related cirrhosis. J Viral Hepat 2001; 8: 3919.
  • 13
    Rosenau J, Bahr MJ, Tillmann HL, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895902.
  • 14
    Zimmerman MA, Ghobrial RM, Tong MJ, et al. Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B. Transpl Proc 2007; 39: 327680.
  • 15
    Samuel D. Liver transplantation and hepatitis B virus infection: the situation seems to be under control, but the virus is still there. J Hepatol 2001; 34: 9435.
  • 16
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 174351.
  • 17
    Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 80816.
  • 18
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 8007.
  • 19
    Tan J, Lok AS. Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B. Liver Transpl 2007; 13: 3236.
  • 20
    Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 34960.
  • 21
    Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 50739.
  • 22
    Tenney D, Pokorowski KA, Rose RE, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2008; 2: S77.
  • 23
    Schiff E, Simsek H, Lee WM, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008; 103: 277683.
    Direct Link:
  • 24
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 22742.
  • 25
    Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 257688.
  • 26
    Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 244255.
  • 27
    Heathcote EJ, Gane EJ, DeMan RA, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis. Hepatology 2008; 48 (Suppl.): 376A.
  • 28
    Marcellin P, Buti M, Krastev Z, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (study 102), preliminary analysis. Hepatology 2008; 48 (Suppl.): 370A.
  • 29
    Van Bommel F, De Man R, Stein K, et al. A multicenter analysis of antiviral response after one year of tenofovir mono-therapy in HBV-monoinfected patients with prior nucleos(t)ide analog experience. J Hepatol 2008; 48 (Suppl. 2): S32.
  • 30
    Taltavull TC, Chahri N, Verdura B, et al. Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results. Transpl Int 2005; 18: 87983.
  • 31
    Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006; 26: 16270.
  • 32
    Murray KF, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41: 140732.
  • 33
    Fontana RJ, Keeffe EB, Carey W, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002; 8: 4339.
  • 34
    Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 71927.
  • 35
    Zoulim F, Radenne S, Ducerf C. Management of patients with decompensated hepatitis B virus association cirrhosis. Liver Transpl 2008; 14 (Suppl. 2): S17.
  • 36
    Fontana RJ, Lok AS. Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when? J Hepatol 2000; 33: 32932.
  • 37
    Lake J. Do we really need long-term hepatitis B hyperimmune globulin? What are the alternatives? Liver Transpl 2008; 14: S2326.
  • 38
    Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 118995.
  • 39
    Angus PW, Patterson SJ. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transpl 2008; 14: S1522.
  • 40
    Neff GW, O'brien CB, Nery J, et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004; 10: 13728.
  • 41
    McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 135864.
  • 42
    Sawyer RG, McGory RW, Gaffey MJ, et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998; 227: 84150.
  • 43
    Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 132733.
  • 44
    Hooman N, Rifai K, Hadem J, et al. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl 2008; 14: 43542.
  • 45
    Van Hoek B, Kroes AC, Ringers J, et al. Switching intravenous to out-of-hospital fixed-dose intramuscular hepatitis B immunoglobulin after liver transplantation for HBsAg-positive HBV-DNA negative cirrhosis is feasible and reduces cost. Hepatology 2000; 32: 242A.
  • 46
    Hunt CM, McGill JM, Allen ML, Condreay LD. Clinical relevance of hepatitis B virus mutations. Hepatology 2000; 31: 103744.
  • 47
    Loomba R, Rowley AK, Wesley R, et al. Hepatitis B immunoglobulin and lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 696700.
  • 48
    Mutimer D, Dusheiko G, Barrett C, et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000; 70: 80915.
  • 49
    Malkan G, Cattral MS, Humar A, et al. Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation 2000; 69: 14037.
  • 50
    Wai CT, Lim SG, Tan KC. Outcome of lamivudine resistant hepatitis B virus infection in liver transplant recipients in Singapore. Gut 2001; 48: 581.
  • 51
    Fontana RJ, Keefe EB, Han S, et al. Prevention of recurrent hepatitis B infection following liver transplantation: experience in 112 North American patients. Hepatology 1999; 30: 301A.
  • 52
    Chan HL, Chui AK, Lau WY, et al. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis. Clin Transpl 2004; 18: 295300.
  • 53
    Zheng S, Chen Y, Liang T, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl 2006; 12: 2538.
  • 54
    Katz L, Paul M, Guy D, et al. Prevention of recurrent hepatitis B virus infection after liver transplantation: HBIG, anti-viral drugs, or both? Systematic review and meta-analysis. Hepatology 2008; 48 (Suppl.): 573A.
  • 55
    Karasu Z. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation. Antivir Ther 2004; 9: 9217.
  • 56
    Ferretti G, Merli M, Ginanni CS, et al. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transpl Proc 2004; 36: 5358.
  • 57
    Dumortier J, Chevallier P, Scoazec JY, et al. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transpl 2003; 3: 9991002.
  • 58
    Sousa JM, Pareja F, Serrano J, et al. Comparison between levels of anti-HBS with a fixed administration dose of HBIG and a combination of HBIG and lamivudine for the prophylaxis of hepatitis B after liver transplantation. Transpl Proc 2003; 35: 7234.
  • 59
    Anselmo DM, Ghobrial RM, Jung LC, et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002; 235: 6119.
  • 60
    Honaker MR, Shokouh-Amiri MH, Vera SR, et al. Evolving experience of hepatitis B virus prophylaxis in liver transplantation. Transpl Infect Dis 2002; 4: 13743.
  • 61
    Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 152835.
  • 62
    Seehofer D, Rayes N, Naumann U, et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001; 72: 13815.
  • 63
    Lee PH, Hu RH, Tsai MK, et al. Liver transplantation for patients with hepatitis B: prevention of hepatitis B recurrence by intravenous antihepatitis B immunoglobulin and lamivudine. Transpl Proc 2000; 32: 22457.
  • 64
    Han SH, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 7418.
  • 65
    Angus PW, McCaughan GW, Gane EJ, et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 42933.
  • 66
    McCaughan GW, Spencer J, Koorey D, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 5129.
  • 67
    Yoshida EM, Erb SR, Partovi N, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 5205.
  • 68
    Yao FY, Osorio RW, Roberts JP, et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5: 4916.
  • 69
    Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 5859.
  • 70
    Marzano A, Lampertico P, Mazzaferro V, et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005; 11: 5328.
  • 71
    Karademir S, Astarcioglu H, Akarsu M, et al. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. Transpl Proc 2006; 38: 57983.
  • 72
    Nath DS, Kalis A, Nelson S, et al. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transpl 2006; 20: 20610.
  • 73
    Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 9317.
  • 74
    Yoshida H, Kato T, Levi D. Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. Clin Transplant 2007; 21: 16671.
  • 75
    Jiao ZY, Jiao Z. Prophylaxis of recurrent hepatitis B in Chinese patients after liver transplantation using lamivudine combined with hepatitis B immune globulin according to the titer of antibody to hepatitis B surface antigen. Transpl Proc 2007; 39: 15336.
  • 76
    Neff GW, Kemmer N, Kaiser TE, et al. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin. Dig Dis Sci 2007; 52: 2497500.
  • 77
    Akyildiz M, Karasu Z, Zeytunlu M, et al. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol 2007; 22: 21304.
  • 78
    Buti M, Mas A, Prieto M, et al. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 2007; 84: 6504.
  • 79
    Takaki A, Yagi T, Iwasaki Y, et al. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation 2007; 83: 2313.
  • 80
    Freshwater DA, Dudley T, Cane P, Mutimer DJ. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation 2008; 85: 110511.
  • 81
    Yilmaz N, Shiffman ML, Todd SR, et al. Prophylaxis against recurrence of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years. Liver Int 2008; 28: 728.
  • 82
    Angus P, Patterson SJ, Strasser S, et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplant hepatitis B prophylaxis. Hepatology 2008; 48: 14606.
  • 83
    Ahn S, Dodson SF, Cohen SM. Oral antiviral therapy without long term maintenance hepatitis B immunoglobulin to prevent hepatitis B recurrence in liver transplant patients. J Hepatol 2008; 48 (Suppl. 2): S734.
  • 84
    Giusto M, Gentilli F, Loria I, et al. Combined therapy with low dose hepatitis B immunoglobulin (HBIG) and lamivudine (LAM) in patients transplanted for HBV chronic liver disease: long term efficacy and costs. J Hepatol 2008; 48 (Suppl. 2): S84.
  • 85
    Lok ASF, Han SB, Schiff ER, et al. HBV recurrence rate post-liver transplantation (OLT) and associated factors: results of the NIH-HBV-OLT study. Hepatology 2008; 48 (Suppl.): 571A.
  • 86
    Lo CM, Liu CL, Lau GK, et al. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005; 11: 80713.
  • 87
    Caccamo L, Romeo R, Rossi G, et al. No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants. Transpl Int 2005; 18: 18692.
  • 88
    Yang Y, Zhang Q, Cai CJ, et al. Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant. Chin Med J 2007; 120: 14003.
  • 89
    Osborn MK, Han SH, Regev A, et al. Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol 2007; 5: 145461.
  • 90
    Villet S, Pichoud C, Villeneuve JP, et al. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131: 125361.
  • 91
    Terrault NA, Wright TL. Combined short-term hepatitis B immunoglobulin (HBIG) and long-term lamivudine (LAM) versus HBIG monotherapy as hepatitis B virus (HBV) prophylaxis in liver transplant recipients. Hepatology 1998; 28: 389A.
  • 92
    Buti M, Mas A, Prieto M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38: 8117.
  • 93
    Naoumov NV, Lopes AR, Burra P, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34: 88894.
  • 94
    Dodson SF, De Vera ME, Bonham CA, et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000; 6: 4349.
  • 95
    Wong SN, Chu CJ, Wai CT, et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007; 13: 37481.
  • 96
    Gane EJ, Strasser S, Patterson SJ, et al. A prospective study on the safety and efficacy of lamivudine and adefovir prophylaxis in HBsAg positive liver transplantation candidates. Hepatology 2007; 46: 479A.
  • 97
    Lenci I, Tisone G, Di Paolo D, et al. Total and covalently closed circular DNA (cccDNA) detection in post-transplant liver biopsies of HBV-positive patients who underwent liver transplantation with undetectable viremia. Hepatology 2008; 48 (Suppl.): 573A.
  • 98
    Sanchez-Fueyo A, Rimola A, Grande L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31: 496501.
  • 99
    Angelico M, Di Paolo D, Trinito MO, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002; 35: 17681.
  • 100
    Bienzle U, Gunther M, Neuhaus R, Neuhaus P. Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results. Liver Transpl 2002; 8: 5624.
  • 101
    Di Paolo D, Lenci I, Trinito MO, et al. Extended double-dosage HBV vaccination after liver transplantation is ineffective, in the absence of lamivudine and prior wash-out of human Hepatitis B immunoglobulins. Dig Liver Dis 2006; 38: 74954.
  • 102
    Lo CM, Liu CL, Chan SC, et al. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol 2005; 43: 2837.
  • 103
    Angelico M, Di Paolo D, Lenci I, et al. One-year extended anti-HBV vaccination with MPL-adjuvanted vaccine combined with anti-HBs immunoglobulins in patients transplanted for HBV-related cirrhosis. Hepatology 2008; 48 (Suppl.): 584A.
  • 104
    Takaki A, Yagi T, Iwasaki Y, et al. Low-dose hepatitis B immunoglobulin with lamivudine for post-transplantation hepatitis B virus reactivation and monthly hepatitis B vaccine application is reliable, cost-effective treatment strategies. Hepatology 2008; 48 (Suppl.): 586A.
  • 105
    Perrillo R, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999; 29: 15816.
  • 106
    Seehofer D, Rayes N, Bechstein WO, et al. Therapy of recurrent hepatitis B infection after liver transplantation. A retrospective analysis of 200 liver transplantations based on hepatitis B associated liver diseases. Z Gastroenterol 2000; 38: 77383.
  • 107
    Fontana RJ, Hann HW, Wright T, et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001; 7: 50410.
  • 108
    Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001; 7: 1137.
  • 109
    Rayes N, Seehofer D, Hopf U, et al. Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation. Transplantation 2001; 71: 96101.
  • 110
    Ben-Ari Z, Pappo O, Zemel R, et al. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis. Transplantation 1999; 68: 2326.
  • 111
    Peters MG, Singer G, Howard T, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999; 68: 19124.
  • 112
    Beckebaum S. Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation. Clin Transpl 2003; 17: 5549.
  • 113
    Akay S, Karasu Z, Akyildiz M, Tokat Y. Adefovir treatment in posttransplant hepatitis B virus infection resistant to lamivudine plus hepatitis B virus immunoglobulin. Transpl Proc 2004; 36: 276870.
  • 114
    Wai CT, Prabhakaran K, Wee A, et al. Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant. Transpl Proc 2004; 36: 23134.
  • 115
    Toniutto P, Fumo E, Caldato M, et al. Favourable outcome of adefovir–dipivoxil treatment in acute de novo hepatitis B after liver transplantation. Transplantation 2004; 77: 4723.
  • 116
    Barcena R. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. Transpl Proc 2005; 37: 39602.
  • 117
    Lilly L, Therapondos G, Mason AL, Burak KW. Tenofovir is effective in suppressing HBV replication in liver transplant recipients with nucleos(t)ide resistant recurrent disease. Hepatology 2008; 48 (Suppl.): 574A.
  • 118
    Kamar N, Milioto O, Alric L, et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008; 86: 6114.
  • 119
    Shakil OA, Lilly L, Angus P, et al. Entecavir significantly reduces viral load in liver transplant recipients failing lamivudine therapy for chronic hepatitis B infection. J Hepatol 2002; 36 (Suppl. 1): 122.